FHIR Clinical Guidelines (v1.0.0) (STU1)
This page is part of the Clinical Guidelines (v1.0.0: STU 1) based on FHIR R4. This is the current published version in it's permanent home (it will always be available at this URL). For a full list of available versions, see the Directory of published versions 
Generated Narrative
knowledgeCapability: shareable
knowledgeCapability: computable
knowledgeCapability: publishable
knowledgeRepresentationLevel: structured
partOf: http://hl7.org/fhir/uv/cpg/PlanDefinition/chf-hypervolemia
enabled: true
url: http://hl7.org/fhir/uv/cpg/PlanDefinition/chf-lasix
version: 1.0.0
name: CHFLASIX
title: CHF LASIX
type: ECA Rule
status: draft
experimental: true
date: Feb 11, 2021 8:30:11 PM
publisher: HL7 International - Clinical Decision Support WG
description: Administer LASIX IV, transition to PO as appropriate
jurisdiction: World
| - | Description | Start |
| * | Transition to LASIX PO | Admission to hospital |
action
Ids
- * title: LASIX IV
description: Administer LASIX IV
code: Dispense Medications
condition
kind: stop
Expressions
- * definition: http://hl7.org/fhir/uv/cpg/ActivityDefinition/chf-lasix-iv
action
Ids
- * title: LASIX PO
description: Administer LASIX PO
code: Dispense Medications
condition
kind: start
Expressions
- * definition: http://hl7.org/fhir/uv/cpg/ActivityDefinition/chf-lasix-po
© HL7.org (Clinical Decision Support WG). hl7.fhir.uv.cpg#1.0.0 based on FHIR v4.0.1. Generated 2021-02-11.
Links: Home
| QA Report
| Version History
| 
| Propose a change